{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T01:30:42Z","timestamp":1768267842643,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"vor","delay-in-days":1436,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Clinical Support Platform for Cancer Research Auvergne Rh\u00f4ne Alpes","award":["23044\u20ac"],"award-info":[{"award-number":["23044\u20ac"]}]},{"name":"French National Society of Internal Medicine","award":["10000\u20ac"],"award-info":[{"award-number":["10000\u20ac"]}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1002\/rth2.12161","type":"journal-article","created":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T00:09:26Z","timestamp":1544746166000},"page":"89-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Thrombin generation in newly diagnosed multiple myeloma during the first three cycles of treatment: An observational cohort study"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0879-6261","authenticated-orcid":false,"given":"Emilie","family":"Chalayer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Tardy\u2010Poncet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel","family":"Karlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Chapelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Montmartin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mich\u00e8le","family":"Piot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Guyotat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Collet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Lecompte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Tardy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1002\/rth2.12161_bb0010","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1002\/cncr.23062","article-title":"Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients","volume":"110","author":"Khorana","year":"2007","journal-title":"Cancer"},{"key":"10.1002\/rth2.12161_bb0015","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"key":"10.1002\/rth2.12161_bb0020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high\u2010dose dexamethasone versus lenalidomide plus low\u2010dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open\u2010label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1002\/rth2.12161_bb0025","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","article-title":"Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open\u2010label, randomized trial","volume":"29","author":"Palumbo","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1002\/rth2.12161_bb0030","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3324\/haematol.2012.064444","article-title":"Thrombosis is associated with inferior survival in multiple myeloma","volume":"97","author":"Kristinsson","year":"2012","journal-title":"Haematologica"},{"key":"10.1002\/rth2.12161_bb0035","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1538-7836.2011.04215.x","article-title":"Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta\u2010analysis","volume":"9","author":"Carrier","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12161_bb0040","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/cncr.26302","article-title":"Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis","volume":"118","author":"Anaissie","year":"2012","journal-title":"Cancer"},{"key":"10.1002\/rth2.12161_bb0045","doi-asserted-by":"crossref","first-page":"E455","DOI":"10.1002\/ajh.24454","article-title":"Usual risk factors do not predict venous thromboembolism in newly diagnosed myeloma treated with immunomodulatory drugs","volume":"91","author":"Chalayer","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1002\/rth2.12161_bb0050","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.thromres.2016.05.003","article-title":"Does the choice of thrombotic prophylactic drug depend on the known risk factors of patients with multiple myeloma in clinical practice?","volume":"143","author":"Chalayer","year":"2016","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12161_bb0055","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.thromres.2016.08.008","article-title":"Cost\u2010effectiveness analysis of low\u2010molecular\u2010weight heparin versus aspirin thromboprophylaxis in patients newly diagnosed with multiple myeloma","volume":"145","author":"Chalayer","year":"2016","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12161_bb0060","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000073575","article-title":"The calibrated automated thrombogram (CAT): a universal routine test for hyper\u2010 and hypocoagulability","volume":"32","author":"Hemker","year":"2002","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1002\/rth2.12161_bb0065","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2010.32.8294","article-title":"Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study","volume":"29","author":"Ay","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1002\/rth2.12161_bb0070","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1111\/j.1538-7836.2009.03561.x","article-title":"Peak thrombin generation and subsequent venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE) study","volume":"7","author":"Lutsey","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12161_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcmd.2017.03.010","article-title":"Thrombin generation as a predictor of thromboembolic events in multiple myeloma patients","volume":"65","author":"Leiba","year":"2017","journal-title":"Blood Cells Mol Dis"},{"key":"10.1002\/rth2.12161_bb0080","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/10428194.2016.1219900","article-title":"Baseline and treatment\u2010related changes in thrombin generation in patients with multiple myeloma","volume":"58","author":"Tiong","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1002\/rth2.12161_bb0085","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1089\/152581601753193869","article-title":"Bleeding diathesis in multiple myeloma","volume":"10","author":"Saif","year":"2001","journal-title":"J Hematother Stem Cell Res"},{"key":"10.1002\/rth2.12161_bb0090","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.3109\/10428194.2015.1041385","article-title":"Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma","volume":"56","author":"Gracheva","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1002\/rth2.12161_bb0095","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/1076029615625825","article-title":"Plasma thrombin generation and sensitivity to activated protein C among patients with myeloma and monoclonal gammopathy of undetermined significance","volume":"22","author":"Crowley","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"issue":"Suppl C","key":"10.1002\/rth2.12161_bb0100","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bcmd.2017.08.011","article-title":"Hypocoagulability as assessed by thrombin generation test in newly\u2010diagnosed patients with multiple myeloma","volume":"66","author":"Legendre","year":"2017","journal-title":"Blood Cells Mol Dis"},{"key":"10.1002\/rth2.12161_bb0105","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.critrevonc.2017.03.014","article-title":"Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: an overview of systematic reviews with meta\u2010analyses","volume":"113","author":"Aguiar","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1002\/rth2.12161_bb0110","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.clml.2011.03.006","article-title":"Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide\/lenalidomide\u2010based therapy: review of data from phase 3 trials and studies of novel combination regimens","volume":"11","author":"Zangari","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1002\/rth2.12161_bb0115","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/s00277-012-1520-4","article-title":"(Bortezomib plus lenalidomide\/thalidomide)\u2010 vs (bortezomib or lenalidomide\/thalidomide)\u2010containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta\u2010analysis of randomized controlled trials","volume":"91","author":"Wang","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1002\/rth2.12161_bb0120","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","article-title":"Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide","volume":"119","author":"Larocca","year":"2012","journal-title":"Blood"},{"key":"10.1002\/rth2.12161_bb0125","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2009-12-257519","article-title":"High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study","volume":"116","author":"Libourel","year":"2010","journal-title":"Blood"},{"key":"10.1002\/rth2.12161_bb0130","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2141.2006.06208.x","article-title":"Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism","volume":"134","author":"Elice","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1002\/rth2.12161_bb0135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1477-9560-4-11","article-title":"Acquired activated protein C resistance and thrombosis in multiple myeloma patients","volume":"4","author":"Jim\u00e9nez\u2010Zepeda","year":"2006","journal-title":"Thromb J"},{"key":"10.1002\/rth2.12161_bb0140","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3324\/haematol.10454","article-title":"Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma","volume":"92","author":"Auwerda","year":"2007","journal-title":"Haematologica"},{"key":"10.1002\/rth2.12161_bb0145","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.leukres.2007.12.002","article-title":"Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens","volume":"32","author":"van Marion","year":"2008","journal-title":"Leuk Res"},{"key":"10.1002\/rth2.12161_bb0150","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1055\/s-0037-1615590","article-title":"Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis","volume":"94","author":"van Marion","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1002\/rth2.12161_bb0155","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/MBC.0000000000000315","article-title":"Induction therapy alters plasma fibrin clot properties in multiple myeloma patients: association with thromboembolic complications","volume":"26","author":"Undas","year":"2015","journal-title":"Blood Coagul Fibrinolysis"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Frth2.12161","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922015084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922015084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/rth2.12161\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:17:13Z","timestamp":1762863433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037922015084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S2475037922015084"],"URL":"https:\/\/doi.org\/10.1002\/rth2.12161","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombin generation in newly diagnosed multiple myeloma during the first three cycles of treatment: An observational cohort study","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/rth2.12161","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 The Authors. Research and Practice in Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}]}}